Taxotere, Docetaxel News

The positive opinion issued by the European Committee for Medicinal Products for Human Use is for the use of Avastin in combination with paclitaxel or docetaxel chemotherapy for the first-line treatment of patients with metastatic breast cancer.

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ -- OncoGenex Pharmaceuticals, Inc.

Isis Generating Impressive Data Share Presentations at ASCO & ADA Show the Power of Isis Technology At perhaps the two biggest industry trade conferences of the year, the American Society of Clinical Oncology and the American Diabetes Association , Isis Pharmaceuticals and/or its partners presented encouraging pre-clinical and early-stage clinical ...

VITAL study: 2nd-line non-small cell lung cancer in combination with docetaxel -- VANILLA study: 1st-line pancreatic cancer in combination with gemcitabine -- VENICE study: 1st-line hormone-refractory metastatic prostate cancer in combination with docetaxel and prednisone Each study is over 60 percent enrolled and initial data from the Phase 3 ...

As first-line therapy for metastatic breast cancer, nab-paclitaxel , a solvent-free formulation of the drug, significantly improves progression-free survival compared with use of docetaxel, researchers report in the Journal of Clinical Oncology for May 26.

With Vandetanib In Patients With Advanced Non-Small Cell Lung Cancer Presented At American Society Of Clinical Oncology Main Category: Lung Cancer Also Included In: Cancer / Oncology Article Date: 04 Jun 2009 - 0:00 PDT Data from the Phase III ZODIAC1 study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, ...

Preliminary data from the Phase II portion of a study in patients with advanced non-small cell lung cancer and a Phase I study of IPI-504 in combination with Taxotere demonstrated anti-tumour activity, including four partial responses in the Phase II, and a generally well-tolerated safety profile in both studies.

Cancer develops when cells known as cancer stem cells begin to divide in an uncontrolled manner.

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.

Video: Phase III Study Data With Vandetanib ) in Patients With Advanced Non-Small Cell Lung Cancer Presented at American Society of Clinical Oncology ORLANDO, Fla.

Isis Pharmaceuticals, Inc. announced today that Isis' collaborators presented new clinical data on drugs in Isis' partnered oncology franchise at this year's American Society of Clinical Oncology Annual Meeting in Orlando, Florida.

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

A gene well known to stop or suppress cancer plays a role in cancer stem cells, according to a new study from the University of Michigan Comprehensive Cancer Center.

The phase Ib clinical trial presented at ASCO investigates the safety and tolerability of increasing doses of adecatumumab given every 3 weeks in combination with standard chemotherapy docetaxel in relapsed MBC patients who had a median of three prior chemotherapy regimens .

OncoGenex Pharmaceuticals Inc, having demonstrated that its experimental prostate cancer drug extends survival by nearly seven months, is now focused on finding a partner to develop the drug, the company's chief executive said on Sunday.

A new study has found that patients undergoing treatment for advanced head and neck cancers may benefit from the addition of gefinitib to chemotherapy.

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology being held May 29 to June 2, 2009, at the Orange County Convention Center in Orlando, FL.

Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that data from two ongoing clinical trials assessing its lead compound bavituximab for the treatment of cancer will be discussed at the 45th Annual Meeting of the ...

Abraxis BioScience Inc. announced today that final results from an open-label Phase II study evaluating three dose levels of the company's chemotherapy agent ABRAXANE for Injectable Suspension compared to the highest standard dose of Taxotere Injection Concentrate, in the first-line treatment of patients with metastatic breast cancer were ...

CHICAGO, May 26, 2009 - New data show that nab-paclitaxel prolongs investigator-assessed, median progression-free survival by almost seven months versus the highest standard dose of docetaxel in women with metastatic breast cancer.